A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

ClinicalTrials.gov ID: NCT05020236

Public ClinicalTrials.gov record NCT05020236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.

Study identification

NCT ID: NCT05020236
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Pfizer; Industry
Enrollment: 893 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 3, 2021
Primary completion: Feb 25, 2026
Completion: May 30, 2027
Last update posted: Aug 23, 2026

2021 – 2027

United States locations

U.S. sites: 26
U.S. states: 6
U.S. cities: 20

Facility	City	State	ZIP	Site status
Clovis Community Medical Center	Clovis	California	93611	Active, not recruiting
Community Cancer Institute	Clovis	California	93611	Active, not recruiting
University of California San Francisco	Fresno	California	93701	Active, not recruiting
Community Regional Medical Center	Fresno	California	93721	Active, not recruiting
UCHealth Poudre Valley Hospital	Fort Collins	Colorado	80524	Active, not recruiting
UCHealth Harmony	Fort Collins	Colorado	80528	Active, not recruiting
UCHealth Greeley Hospital	Greeley	Colorado	80634	Active, not recruiting
UCHealth - Medical Center of the Rockies	Loveland	Colorado	80538	Active, not recruiting
Sylvester Comprehensive Cancer Center - Aventura	Aventura	Florida	33180	Recruiting
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center	Coral Gables	Florida	33146	Recruiting
Sylvester Comprehensive Cancer Center - Coral Springs	Coral Springs	Florida	33065	Recruiting
University of Miami Hospital and Clinics - Deerfield Beach	Deerfield Beach	Florida	33442	Recruiting
Sylvester Comprehensive Cancer Center - Hollywood	Hollywood	Florida	33021	Recruiting
Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Recruiting
University of Miami Hospital and Clinics	Miami	Florida	33136	Recruiting
Sylvester Comprehensive Cancer Center - Kendall	Miami	Florida	33176	Recruiting
Sylvester Comprehensive Cancer Center - Plantation	Plantation	Florida	33324	Recruiting
East Jefferson General Hospital	Metairie	Louisiana	70006	Active, not recruiting
MSK Basking Ridge	Basking Ridge	New Jersey	07920	Recruiting
MSK Monmouth	Middletown	New Jersey	07748	Recruiting
MSK Bergen	Montvale	New Jersey	07645	Recruiting
MSK Commack	Commack	New York	11725	Recruiting
MSK Westchester	Harrison	New York	10604	Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York	New York	10021	Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus	New York	New York	10065	Recruiting
MSK Nassau	Uniondale	New York	11553	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 211 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05020236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 23, 2026 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05020236 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →